Liver steatosis is emerging as a major cause of chronic liver disease worldwide, mainly due to the increasing rate of obesity, type 2 diabetes, and metabolic syndrome. Because of the increased incidence of liver steatosis, many organs are currently declined for transplantation despite high demand and waiting list mortality. Defatting strategies have recently emerged as a means of rapidly reducing liver steatosis to expand the pool of available organs. This review summarises advances in defatting strategies in experimental and human models of liver steatosis over the last 20 years. © 2021 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).
Laura Ioana Mazilescu, Markus Selzner, Nazia Selzner. Defatting strategies in the current era of liver steatosis. JHEP reports : innovation in hepatology. 2021 Jun;3(3):100265
PMID: 34027337
View Full Text